FibroGen Shares Are Trading Lower After the Company's Phase 3 Trial of Pamrevlumab Did Not Meet Its Primary Endpoint.
在該公司的Pamrevlumab第三階段試驗未達到其主要終點之後,FibroGen股價走低。
FibroGen Shares Are Trading Lower After the Company's Phase 3 Trial of Pamrevlumab Did Not Meet Its Primary Endpoint.
在該公司的Pamrevlumab第三階段試驗未達到其主要終點之後,FibroGen股價走低。
使用瀏覽器的分享功能,分享給你的好友吧